ABSTRACT: Congenital hypogonadotropic hypogonadism (CHH), which can present with a defective sense of smell (Kallmann syndrome, KS), is a clinically and genetically heterogeneous disorder. Over 31 genes have been associated with CHH, but most of the patients still lack a molecular genetic diagnosis. Some cases may be explained by mutations that disrupt the splicing of already established CHH genes but that are unrecognized either because they are located deep in introns or are not predicted to disrupt splicing. Here we identified a patient with a previously unreported Fibroblast Growth Factor Receptor 1 (FGFR1) mutation, c.1664-9T>G, that leads to the skipping of exon 13 of FGFR1. Notably, the mutation was not predicted to cause a significant alteration in the splicing motif but in vitro analysis confirmed the pathogenicity of the mutation. Our results thus reveal a new splicing-affecting mutation in FGFR1 and suggest that all new sequence variants located close to exon/intron boundaries should be experimentally investigated for pathogenicity, rather than relying solely on computer prediction programs.
Introduction
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder characterized by delayed, absent, or partial pubertal development that is caused by an insufficient number of hypothalamic gonadotropin-releasing hormone (GnRH)-secreting neurons, deficient GnRH secretion, or defective GnRH action (Boehm et al., 2015; Kim, 2015; Forni & Wray, 2015) . Kallmann syndrome (KS) is a syndromic form of CHH that is explained by the tightly interconnected development of the GnRH neurons and the olfactory system (Forni & Wray, 2015) . CHH is a very heterogeneous disorder both clinically and genetically, and over 31 genes have already been associated with the disease (Kim, 2015) . Mutations in any single gene, however, account for only a small percentage of the cases. Mutations in FGFR1, encoding Fibroblast Growth Factor Receptor 1, are the most common identified genetic cause of CHH, but they account for only approximately 10% of the cases; the second most often mutated gene is ANOS1 with mutations found in approximately 5-10% of the cases (Bianco & Kaiser, 2009; Miraoui et al., 2013) .
Although new CHH genes are probably yet to be discovered, noncoding variation in the already established CHH genes might underlie some of the cases with an unidentified genetic cause. An example of this kind of variation are mutations affecting splicing that are unrecognized either because they are located deep in introns or are not predicted to disrupt splicing. We report here a novel intronic FGFR1 mutation that was not predicted to affect splicing in silico but that the patient's cDNA screening and an in vitro mini-gene assay later revealed to lead to abnormal splicing of FGFR1 mRNA.
Case report

Methods
The new FGFR1 mutation was identified in a proband with KS who had been screened for mutations in the coding exons and conserved splice sites of ANOS1, FGFR1, FGF8, PROK2, PROKR2, CHD7, WDR11, SOX10, SEMA3A and SEMA7A (Laitinen et al., 2011; Känsäkoski et al., 2014 . He was originally diagnosed with KS on the basis of absent sense of smell and hypogonadotropic hypogonadism at the age of 18 years. At the age of 56 years, he participated in the current study and was found to have absent olfactory bulbs in magnetic resonance imaging (Laitinen et al., 2011) . He had two brothers, one with normal sense of smell and another one with anosmia. Their mother did not carry the FGFR1 mutation, and their apparently fertile father had deceased prior to this study.
The patient's RNA was extracted from fresh whole blood with the QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions and converted to cDNA with SuperScript III First-Strand Synthesis System (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA). The FGFR1 cDNA (NM_023110) was PCR-amplified, purified with Illustra ExoProStar treatment (GE Healthcare, Chicago, IL, USA) and bi-directionally sequenced in overlapping fragments by using the ABI BigDyeTerminator Cycle Sequencing Kit (v3.1) and ABI Prism 3730xl DNA Analyzer automated sequencer (Applied Biosystems, Thermo Fisher Scientific, Waltham, Massachusetts, USA). The sequences were aligned and read with Sequencher ® 5.0 software (Gene Codes Corporation, Ann Arbor, MI, USA). All primer sequences used in the screening are listed in Supplementary Table S1 . PCR conditions are available upon request.
The pathogenicity of the FGFR1 mutation was analyzed by a minigene experiment. Briefly, FGFR1 exon 13 and the flanking introns were cloned into pET01 Exontrap vector (MoBiTec GmbH, Göttingen, Germany), and the WT and mutant constructs were transiently expressed in AtT-20 cells, RNA was extracted (NucleoSpin RNA, Macherey-Nagel GmbH & Co. KG, Düren, Germany) and reversetranscriptase-PCR (SuperScript III One-Step RT-PCR, Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) was performed with primers located on each of the flanking exons. The PCR products were analyzed on a 1.5% (w/v) agarose gel and confirmed by Sangersequencing. 
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Results
cDNA analysis revealed skipping of FGFR1 exon 13 (Fig. 1) . Only one candidate mutation, c.1664-9T>G (NM_023110), located 9 bp On the left, PCR products obtained with primers targeting FGFR1 exons 9 and 14 (cFGFR1F3 and R3) visualized on a 2% agarose gel. The normal-sized product size is 819 bp, and the product obtained from the mutated allele is 628 bp. S1: cDNA of the patient with the intronic FGFR1 mutation. The patient has a heterozygous mutation and therefore the amplification yields both the normal product and the product missing exon 13. S2: cDNA of a patient without the mutation. DNA ladder: GeneRuler 100 bp DNA ladder (Thermo Scientific). On the right, RT-PCR-amplification of the mini-gene construct mRNA was performed with primers targeting the flanking (5′ and 3′) exons of the phosphatase gene, and the products were analyzed on a 1.5% agarose gel. The expected size of the RT-PCR product is 459 bp when the exon 13 of FGFR1 in included (WT lane) and 268 bp when it is spliced out due to the indicated point mutation in intron 12 (mutant lane).
upstream of exon 13, was found when the entire intron 12, exon 13 and intron 13 genomic sequences were examined (Fig. 1A) . Surprisingly, Human Splicing Finder (http://www.umd.be/HSF3/ index.html, 28 November 2017, date last accessed) did not detect any significant alteration in the splicing motif [−3.35% variation in acceptor site motif with HSF algorithm; WT score: 92.5, mutant score: 89.4 (consensus value (CV) threshold 65, variation threshold ±10%); −23.25% variation in acceptor site motif with MaxEntScan algorithm; WT score: 11.87, mutant score: 9.11 (CV threshold 3, variation threshold ±30%)]. Additionally, NNSplice (http://www.fruitfly.org/ seq_tools/splice.html, 28 November 2017, date last accessed) showed only a mild reduction in the score for the acceptor splice site (WT score: 0.95, mutant score: 0.84). The mutation segregated in the family where it was found in heterozygous state in the index patient and in his anosmic brother, but not in the healthy brother (Fig. 1A) (Fig. 1C) , which again revealed the skipping of FGFR1 exon 13 to be caused by the c.1664-9T>G mutation (Fig. 1D) . The skipping of exon 13 is predicted to lead to a frameshift and a premature termination codon after 36 novel amino acids.
Discussion
In this study, we identified a novel splicing-affecting mutation, c.1664-9T>G, in FGFR1. The mutation was not initially suspected as a causal variant because it is not predicted to lead to a significant alteration in the acceptor splicing motif of exon 13. The investigation of FGFR1 cDNA, however, enabled the identification of the causal mutation, which was further confirmed with a mini-gene assay. Although computational analysis does not predict a drastic reduction in the strength of the splice site, analysis of the patient's mRNA and the in vitro assay showed that it is sufficient to abolish the functional 3′ splice site of exon 13 in vivo. Variable expressivity, as seen in this family, is typical for FGFR1 mutations.
In conclusion, in silico tools may not always reliably predict altered splicing caused by some splicing-affecting mutations, and consequently, all new sequence variants located close to exon/intron boundaries should be experimentally investigated for pathogenicity.
